Association of liver X receptor α (LXRα) gene polymorphism and coronary heart disease, serum lipids and glucose levels

Lipids in Health and Disease

Hui-Lan Luo¹  Yuan-Yuan Li¹  Xiao-Yan Zhang¹  Jun-JIE Li¹  Qiao-Xiang Yin¹  Jing-Li Miao¹  Zong-Xue Li¹  Jing Zhang²  Yun-Fei Zhou¹ 

[1] The cadre ward of General Hospital of the Air Force PLA, No. 30, Fucheng Road, Haidian District, Beijing 100142, China;Combination of traditional Chinese and Western Medicine Hospital of Southern Medical University, Guangzhou 510515, China

关键词: Polymorphism;    Coronary heart disease;    Gene;    Liver X receptor α;   

Others  :  811318
DOI  :  10.1186/1476-511X-13-34

 received in 2013-12-09, accepted in 2014-02-10,  发布年份 2014

【 摘 要 】

Background

To explore the relationship between the liver X receptor α gene (LXRα) rsl2221497 polymorphism and the susceptibility of coronary heart disease (CHD) and serum lipids and glucose levels.

Methods

The single fluorescently labeled probes technique was used to detect the genotype of rsl2221497 in LXRα gene in 240 CHD patients and 250 healthy control subjects. The difference of genotype distribution between the two groups was analyzed using of Chi-square test. The serum lipids and glucose levels between the different genotypes were also compared.

Results

The risk of CHD in carriers with (AA + GA) genotype was 1.76 times as that in the GG genotype carriers (OR = 1.76, 95% CI: 1.18-2.87, P <0.05), and the risk of CHD in carriers with A allele increased 0.88 times compared to that in G allele carriers (OR = 1.88, 95% CI:1.21-3.43, P <0.01). Logistic regression analysis showed that after adjusting for other confounding factors, A allele was an independent risk for CHD. However, there were no differences in serum lipids and glucose levels between each genotype.

Conclusions

The rsl2221497 polymorphism in LXRα gene was associated with susceptibility of CHD in Han population.

【 授权许可】

   
2014 Zhou et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Fujimoto K, Hayashi A, Kamata Y, Ogawa A, Watanabe T, Ichikawa R, Iso Y, Koba S, Kobayashi Y, Koyama T, Shichiri M: Circulating levels of human salusin-β, a potent hemodynamic and atherogenesis regulator. PLoS One 2013, 8(10):e76714.
• [2]Polfus LM, Smith JA, Shimmin LC, Bielak LF, Morrison AC, Kardia SL, Peyser PA, Hixson JE: Genome-wide association study of gene by smoking interactions in coronary artery calcification. PLoS One 2013, 8(10):e74642.
• [3]Bentham J, Vyse T: The development of genome-wide association studies and their application to complex diseases, including lupus. Lupus 2013, 22(12):1205-1213.
• [4]Inanloorahatloo K, Zand Parsa AF, Huse K, Rasooli P, Davaran S, Platzer M, Fan JB, Amini S, Steemers F, Elahi E: Mutation in CYP27A1 identified in family with coronary artery disease. Eur J Med Genet 2013. doi: 10.1016/j.ejmg.2013.09.008
• [5]Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, Wenzel D, Vosen S, Franklin BS, Fleischmann BK, Nickenig G, Werner N: Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 2013, 128(18):2026-2038.
• [6]Orozco LD, Liu H, Perkins E, Johnson DA, Chen BB, Fan F, Baker RC, Roman RJ: 20-Hydroxyeicosatetraenoic acid inhibition attenuates balloon injury-induced neointima formation and vascular remodeling in rat carotid arteries. J Pharmacol Exp Ther 2013, 346(1):67-74.
• [7]Sharma AK, Arya R, Mehta R, Sharma R, Sharma AK: Hypothyroidism and cardiovascular disease: factors, mechanism and future perspectives. Curr Med Chem 2013, 20(35):4411-4418.
• [8]Zhang X, Liu J, Su W, Wu J, Wang C, Kong X, Gustafsson JA, Ding J, Ma X, Guan Y: Liver X receptor activation increases hepatic fatty acid desaturation by the induction of SCD1 expression through an LXRα-SREBP1c-dependent mechanism. J Diabetes 2013. doi: 10.1111/1753-0407.12081. [Epub ahead of print]
• [9]Jakobsson T, Treuter E, Gustafsson JÅ, Steffensen KR: Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci 2012, 33(7):394-404.
• [10]A-González N, Castrillo A: Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. Biochim Biophys Acta 2011, 1812(8):982-994.
• [11]Faulds MH, Zhao C, Dahlman-Wright K: Molecular biology and functional genomics of liver X receptors (LXR) in relationship to metabolic diseases. Curr Opin Pharmacol 2010, 10(6):692-697.
• [12]Hazra S, Rasheed A, Bhatwadekar A, Wang X, Shaw LC, Patel M, Caballero S, Magomedova L, Solis N, Yan Y, Wang W, Thinschmidt JS, Verma A, Li Q, Levi M, Cummins CL, Grant MB: Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes. Diabetes 2012, 61(12):3270-3279.
• [13]Jia Y, Hoang MH, Jun HJ, Lee JH, Lee SJ: Cyanidin, a natural flavonoid, is an agonistic ligand for liver X receptor alpha and beta and reduces cellular lipid accumulation in macrophages and hepatocytes. Bioorg Med Chem Lett 2013, 23(14):4185-4190.
• [14]Zhao JF, Shyue SK, Lin SJ, Wei J, Lee TS: Excess nitric oxide impairs LXR(α)-ABCA1-dependent cholesterol efflux in macrophage foam cells. J Cell Physiol 2014, 229(1):117-125. doi: 10.1002/jcp.24429
• [15]Watanabe K, Sakurai K, Tsuchiya Y, Yamazoe Y, Yoshinari K: Dual roles of nuclear receptor liver X receptor α (LXRα) in the CYP3A4 expression in human hepatocytes as a positive and negative regulator. Biochem Pharmacol 2013, 86(3):428-436.
• [16]Jin SH, Yang JH, Shin BY, Seo K, Shin SM, Cho IJ, Ki SH: Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction. Toxicol Appl Pharmacol 2013, 271(1):95-105.
• [17]Chen Y, Zhang S, Zhou T, Huang C, McLaughlin A, Chen G: Liver X receptor alpha mediated genistein induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1) in Hep G2 cells. Toxicol Appl Pharmacol 2013, 268(2):106-112.
• [18]Zhang Y, Repa JJ, Gauthier K, Mangelsdorf DJ: Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J Biol Chem 2001, 276(46):43018-43024.
• [19]Zhao JF, Ching LC, Kou YR, Lin SJ, Wei J, Shyue SK, Lee TS: Activation of TRPV1 prevents OxLDL-induced lipid accumulation and TNF-α-induced inflammation in macrophages: role of liver X receptor α. Mediat Inflamm 2013, 2013:925171. doi: 10.1155/2013/925171
• [20]Fan JS, Liu DN, Huang G, Xu ZZ, Jia Y, Zhang HG, Li XH, He FT: Panax notoginseng saponins attenuate atherosclerosis via reciprocal regulation of lipid metabolism and inflammation by inducing liver X receptor alpha expression. J Ethnopharmacol 2012, 142(3):732-738.
• [21]Legry V, Bokor S, Beghin L, Galfo M, Gonzalez-Gross M, Molnar D, Moreno LA, Amouyel P, Dallongeville J, Meirhaeghe A, HELENA Study Group: Associations between common genetic polymorphisms in the liver X receptor alpha and its target genes with the serum HDL-cholesterol concentration in adolescents of the HELENA study. Atherosclerosis 2011, 216(1):166-169.
• [22]Robitaille J, Houde A, Lemieux S, Gaudet D, Pérusse L, Vohl MC: The lipoprotein/lipid profile is modulated by a gene-diet interaction effect between polymorphisms in the liver X receptor-alpha and dietary cholesterol intake in French-Canadians. Br J Nutr 2007, 97(1):11-18.